A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study during which patients with advanced multiple myeloma will receive
either carfilzomib alone (single-agent) or carfilzomib in combination with investigational
study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of
both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will
be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease
progression occurs. Approximately 75 patients from the US will be enrolled in this study.